In the last three months, 713 cases have been reported from 24 countries and areas. Over the past 4 weeks, 289 cases of mpox have been identified from 18 countries and areas.
Since 7 March 2022, a total of 29 607 cases of mpox (formerly named monkeypox) have been identified through IHR mechanisms, official public sources and The European Surveillance System (TESSy) up to 14 April 2025, 14:00, from 47 countries and areas throughout the WHO European Region. Case-based data were reported for 29 455 cases from 43 countries and areas to ECDC and the WHO Regional Office for Europe through TESSy, up to 14 April 2025, 10:00. Of the 29 455 cases reported in TESSy, 0.65% were probable cases.
The majority of cases were male (98%; n = 29 353) with the most affected age group being 31–40 years-old (40%; n = 29 408). Of the 13 132 male cases with known sexual behaviour, 97% were reported as men who have sex with men. Among cases with known HIV status, 37% (n = 12 452) were HIV-positive. The majority of cases presented with a rash (92%; n = 18 726). Systemic symptoms such as fever, fatigue, muscle pain, chills, or headache were present in 60% of cases (n = 18 726). 977 (7%) cases were hospitalised, of which 319 cases required clinical care. Nine cases were admitted to ICU, and 9 cases were reported to have died.
Since August 2024, 23 cases of clade 1b have been detected in 6 countries. All these cases either travelled themselves or are contacts of travelers from countries with known local transmission of clade Ib. Also one case of clade 1a has been detect in Ireland.
An overview of the global situation can be found here: https://worldhealthorg.shinyapps.io/mpx_global/.
This report provides an overview of the total number of cases of mpox (formerly named monkeypox) identified by ECDC and the WHO Regional Office for Europe through IHR mechanisms and official public sources and case-based data through The European Surveillance System (TESSy) up to 14 April 2025.
The first summary table and maps (first two tabs) describe the number of cases identified through the different platforms. The following figures and tables describe national case-based data for surveillance of mpox reported in TESSy from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA).
Case Report Form Data are submitted through the case-based record type mpox (MPX) to The European Surveillance System (TESSy) database hosted at ECDC.
https://www.ecdc.europa.eu/en/publications-data/mpox-mpx-reporting-protocol-2024
Summary of number of cases of mpox reported to TESSy, or identified through IHR mechanisms or official public sources and, WHO European Region, 2022–2025
Countries and areas reporting new cases in the past 4 ISO weeks are highlighted in blue
¹ All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).
Since August 2024, 32 cases of clade 1b have been detected in 6
countries.
Also one case of clade 1a has been detect in Ireland.
All these cases either travelled themselves or are contacts of travelers
from countries with known local transmission of clade Ib, except for one
case in the United Kingdom.
Geographical distribution of confirmed mpox cases in the EU/EEA, Western Balkans and Türkiye, since the previous report as of 14 Apr 2025
Geographical distribution of cumulative confirmed mpox cases per 1 000 000 population in the EU/EEA, Western Balkans and Türkiye, as of 14 Apr 2025
Overall number of cases of mpox, per date of notification, for the whole period and zoom on the last year, WHO European Region, TESSy
Overall number of cases of mpox, per date of notification, for the whole period and zoom on the last year, EU/EEA countries, TESSy
Number of cases of mpox, per day and per country of notification, WHO European Region, TESSy, in the last 12 months
Countries highlighted in the legend are the 8 countries with the highest peak of daily cases in the last 12 months (moving average).